Edwards Lifesciences Corp (EW) Shares Sold by Old Mutual Global Investors UK Ltd.

Old Mutual Global Investors UK Ltd. trimmed its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 46.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 593,518 shares of the medical research company’s stock after selling 507,367 shares during the quarter. Old Mutual Global Investors UK Ltd. owned 0.28% of Edwards Lifesciences worth $66,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LS Investment Advisors LLC increased its stake in shares of Edwards Lifesciences by 6.0% in the 4th quarter. LS Investment Advisors LLC now owns 7,789 shares of the medical research company’s stock worth $878,000 after purchasing an additional 440 shares in the last quarter. Resources Investment Advisors Inc. increased its stake in shares of Edwards Lifesciences by 66.0% in the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock worth $132,000 after purchasing an additional 465 shares in the last quarter. Pacer Advisors Inc. increased its stake in shares of Edwards Lifesciences by 10.4% in the 3rd quarter. Pacer Advisors Inc. now owns 5,312 shares of the medical research company’s stock worth $581,000 after purchasing an additional 499 shares in the last quarter. Rodgers Brothers Inc. increased its stake in shares of Edwards Lifesciences by 1.5% in the 3rd quarter. Rodgers Brothers Inc. now owns 34,250 shares of the medical research company’s stock worth $3,744,000 after purchasing an additional 500 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec increased its stake in shares of Edwards Lifesciences by 1.9% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 26,902 shares of the medical research company’s stock worth $2,953,000 after purchasing an additional 500 shares in the last quarter. 81.11% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have recently commented on the company. JMP Securities upped their price objective on Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, February 2nd. SunTrust Banks restated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, January 31st. Guggenheim restated a “buy” rating and issued a $162.00 price objective on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Barclays reduced their price objective on Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 25th. Finally, Canaccord Genuity restated a “buy” rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $141.15.

Shares of Edwards Lifesciences Corp (EW) opened at $127.35 on Wednesday. Edwards Lifesciences Corp has a 12 month low of $89.20 and a 12 month high of $138.48. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $26,852.45, a price-to-earnings ratio of 33.39, a price-to-earnings-growth ratio of 1.87 and a beta of 0.63.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The business had revenue of $888.50 million during the quarter, compared to analyst estimates of $868.45 million. During the same quarter in the prior year, the business posted $0.75 EPS. Edwards Lifesciences’s revenue for the quarter was up 15.7% compared to the same quarter last year. equities analysts expect that Edwards Lifesciences Corp will post 4.49 earnings per share for the current fiscal year.

Edwards Lifesciences declared that its Board of Directors has authorized a share buyback plan on Thursday, December 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $127.24, for a total transaction of $674,372.00. Following the completion of the transaction, the vice president now owns 24,908 shares in the company, valued at $3,169,293.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,800 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $126.69, for a total value of $4,155,432.00. Following the transaction, the chief executive officer now owns 74,131 shares of the company’s stock, valued at approximately $9,391,656.39. The disclosure for this sale can be found here. Insiders sold a total of 205,530 shares of company stock valued at $24,163,915 in the last quarter. 2.13% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Edwards Lifesciences Corp (EW) Shares Sold by Old Mutual Global Investors UK Ltd.” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/14/edwards-lifesciences-corp-ew-shares-sold-by-old-mutual-global-investors-uk-ltd.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply